Neurocrine Reports Strong Q1 Earnings, Announces $2.9 Billion Acquisition of Soleno Therapeutics, and Reaffirms 2026 Guidance

summarizeSummary

Neurocrine Biosciences reported significantly strong first-quarter 2026 financial results, including a 44% increase in net product sales and a substantial rise in GAAP EPS, alongside announcing a definitive agreement to acquire Soleno Therapeutics for $2.9 billion.

check_boxKey Events

• Strong First-Quarter 2026 Financial Results

  Total net product sales increased 44% year-over-year to $811.0 million. GAAP diluted earnings per share rose significantly to $1.91 from $0.08 in the prior-year period, driven by strong demand for INGREZZA and CRENESSITY.

• Definitive Agreement to Acquire Soleno Therapeutics

  Neurocrine entered into an agreement to acquire Soleno Therapeutics for $2.9 billion in cash, adding VYKAT™ XR for Prader-Willi syndrome and expanding its endocrinology and rare disease portfolio. The acquisition is expected to close in Q2 2026.

• Reaffirmed Full-Year 2026 Financial Guidance

  The company reaffirmed its full-year 2026 INGREZZA net sales guidance of $2.7 billion to $2.8 billion, along with R&D and SG&A expense guidance, excluding post-close expenses from the Soleno acquisition.

• Advancements in Clinical Pipeline

  Neurocrine initiated a Phase 2 clinical study for NBI-1117570 in adults with schizophrenia and a Phase 1 study for NBIP-'2118, a potential first-in-class therapy for obesity.

auto_awesomeAnalysis

Neurocrine Biosciences delivered exceptionally strong first-quarter results, with total net product sales increasing 44% year-over-year and GAAP diluted EPS surging from $0.08 to $1.91. This robust financial performance is further amplified by the definitive agreement to acquire Soleno Therapeutics for $2.9 billion, a strategic move that significantly expands Neurocrine's portfolio with VYKAT™ XR for Prader-Willi syndrome and is expected to accelerate future revenue growth. The reaffirmation of full-year 2026 guidance, despite the strong Q1, suggests management's confidence in continued performance, while new clinical study initiations highlight ongoing pipeline development. This filing presents a highly positive outlook, combining strong operational execution with a major strategic acquisition.